SCHEMBL5203846

SCHEMBL5203846

Nc1ncc(Cc2ccc(Cl)cc2Cl)c(N2CCCC(=O)C2)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.40
HTT P42858 4/20 0.37
ALDH1A1 P00352 3/20 0.37
NPSR1 Q6W5P4 2/20 0.37
KDM4E B2RXH2 1/20 0.37
PDE3B Q13370 1/20 0.37
PDE3A Q14432 1/20 0.37
FFAR1 O14842 1/20 0.37
FFAR4 Q5NUL3 1/20 0.37
DHFR P00374 3/20 0.36
AKT2 P31751 1/20 0.34
MAT2A P31153 1/20 0.34
LMNA P02545 2/20 0.34
INPPL1 O15357 1/20 0.34
NPC1 O15118 1/20 0.34
MAPT P10636 1/20 0.34
PPP1CA P62136 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
GAA P10253 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5207346 0.90 HSP90AA1 (0.36) PDE3BPDE3AFFAR1FFAR4DHFR
SCHEMBL5207721 0.90 TRAP1 (0.36) DHFR
SCHEMBL5207312 0.88 DHFR (0.39) PDE3BPDE3ADHFR
SCHEMBL5206429 0.87 TRAP1 (0.39) SMN1; SMN2HTTALDH1A1KDM4EFFAR1
SCHEMBL5205412 0.87 SMN1; SMN2 (0.43) SMN1; SMN2HTTALDH1A1NPSR1KDM4E
SCHEMBL5206648 0.87 DHFR (0.38) DHFR
SCHEMBL7163401 0.83 ALDH1A1 (0.42) SMN1; SMN2HTTALDH1A1NPSR1KDM4E
SCHEMBL5202556 0.78 DHFR (0.35) DHFR
SCHEMBL5202924 0.78 DHFR (0.43) DHFR
SCHEMBL5202765 0.78 DHFR (0.38) DHFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1165523-B1 NEUROTROPHIC SUBSTITUTED PYRIMIDINES KRENITSKY PHARMACEUTICALS INC (US) 2007-11-07 EP claimed
US-6583148-B1 Neurodegenerative or other neurological disorders; enhancing the effect of nerve growth factor; 2-Amino-5-(4-chlorophenoxy)-4-trans-4-hydroxycyclohexylamino) pyrimidine KRENITSKY PHARMACEUTICALS, INC. 2003-06-24 US claimed
EP-1165523-B1 NEUROTROPHIC SUBSTITUTED PYRIMIDINES KRENITSKY PHARMACEUTICALS INC (US) 2007-11-07 EP disclosed
US-6916820-B1 Neurotrophic substituted pyrimidines KRENITSKY PHARMACEUTICALS, INC. (US) 2005-07-12 US disclosed
US-6583148-B1 Neurodegenerative or other neurological disorders; enhancing the effect of nerve growth factor; 2-Amino-5-(4-chlorophenoxy)-4-trans-4-hydroxycyclohexylamino) pyrimidine KRENITSKY PHARMACEUTICALS, INC. 2003-06-24 US disclosed